Accessibility Menu
Lonza Group Ag logo

Lonza Group Ag(OTC) LZAGF

Current Price$675.41
Market Cap$47.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+1,332%
5 Year-9%
1 Year-2%
1 Month+1%
Lonza Group Ag last closing stock price
MetricPriceDate
Last closeUSD 675.412026-07-24
Lonza Group Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.99%USD 703.512026-07-17
1 month+1.34%USD 666.472026-06-24
3 month+10.86%USD 609.232026-04-24
Year to date+0.3%USD 673.402025-12-31
1 year-1.5%USD 685.692025-07-24
3 year+20.96%USD 558.352023-07-25
5 year-8.69%USD 739.662021-07-23
Since inception+1,331.62%USD 47.182003-07-08

Lonza Group Ag Financials at a Glance

Market Cap

$47.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 13.40B

Net Income (TTM)

CHF 1.80B

EPS (TTM)

-$1.77

P/E Ratio

-385.77

Dividend

$3.19

Beta (Volatility)

0.66 (Low)

Price

$675.41

Volume

64

Open

$689.00

Previous Close

$675.41

Daily Range

$657.00 - $689.00

52-Week Range

$565.14 - $755.96

Estimated Earnings Date

Jul 22, 2026

LZAGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lonza Group Ag

Lonza Group AG, established in 1897 and headquartered in Basel, Switzerland, is a leading global provider of critical products and services for the pharmaceutical, biotechnology, and nutrition sectors. The company operates across multiple regions, including Europe, North America, and Asia, and is organized into four main divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients.

Products and Services
  • Contract development and manufacturing of biopharmaceuticals
  • Development and manufacturing of small molecule active pharmaceutical ingredients
  • Technological solutions for cell and gene therapies
Growth Outlook
  • Projected growth in biopharmaceuticals driven by increasing global demand
  • Expansion in cell and gene therapy markets expected to enhance revenue streams
  • Strategic investments in R&D to foster innovation and competitive advantage
Financial Highlights
  • Recent quarterly revenue of 2.96 billion CHF, showing resilience
  • Trailing twelve months (TTM) revenue of 12.5 billion CHF, indicating strong performance
  • Net income margin of 16.3% in the latest quarter, reflecting operational efficiency
Lonza Group AG has established itself as a key player in the healthcare sector, particularly in the rapidly evolving biopharmaceutical landscape. The company's diverse product offerings and strategic focus on innovation position it well for future growth. Recent financial performance highlights a robust revenue stream, with a significant quarterly revenue figure that underscores the company's resilience in a competitive market. The focus on expanding capabilities in cell and gene therapies aligns with industry trends, suggesting potential for increased market share and profitability. Overall, Lonza Group AG presents a compelling opportunity for investors interested in the healthcare and biotechnology sectors.
AI Generated • Jun 30, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

16,866

CEO

Wolfgang Wienand, PhD

Website

www.lonza.com

Headquarters

Basel, BS 4002, CH

LZAGF Financials

Key Financial Metrics (TTM)

Gross Margin

35.79%

Operating Margin

23.02%

Net Income Margin

-1.74%

Return on Equity

-1.28%

Return on Capital

9.06%

Return on Assets

-0.60%

Earnings Yield

-0.26%

Dividend Yield

0.47%

Payout Ratio

-3.39%

Stock Overview

Market Cap

$47.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

69.84M

Volume

64

Avg. Volume

380.984

Financials (TTM)

Gross Profit

CHF 4.59B

Operating Income

CHF 2.50B

EBITDA

CHF 3.66B

Operating Cash Flow

CHF 2.59B

Capital Expenditure

-CHF 2.74B

Free Cash Flow

-CHF 157.42M

Cash & ST Invst.

CHF 487.00M

Total Debt

CHF 4.17B

Lonza Group Ag Performance Analysis

Lonza Group Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 6,515,786,09010.1%
20232023-12-31CHF 7,474,530,58714.7%
20242024-12-31CHF 6,222,552,302-16.7%
20252025-12-31CHF 7,864,067,67926.4%
Lonza Group Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3115.0%
Q22025-06-301.7%
Q42025-12-31-17.3%
Q22026-06-3013.5%
Lonza Group Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF 17.11-60.4%
20232023-12-31CHF 9.88-42.3%
20242024-12-31CHF 10.132.6%
20252025-12-31CHF -4.73N/A
Lonza Group Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-6.5%
Q22025-06-3040.8%
Q42025-12-31-264.7%
Q22026-06-30184.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 3.36B

+9.7%

Gross Profit

CHF 1.29B

+15.4%

Gross Margin

38.38%

N/A

Market Cap

$47.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.62M

N/A

Employees

17,995

N/A

Net Income

CHF 587.68M

+78.6%

EBITDA

CHF 1.14B

+34.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 487.00M

-75.9%

Total Debt

CHF 4.17B

+9.8%

Accounts Receivable

CHF 1.92B

+23.8%

Inventory

CHF 1.88B

+9.7%

Long Term Debt

CHF 3.39B

-6.8%

Short Term Debt

CHF 774.00M

+399.4%

Return on Assets

-0.60%

N/A

Return on Invested Capital

10.34%

N/A

Free Cash Flow

CHF 80.54M

+168.8%

Operating Cash Flow

CHF 656.29M

+30.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HOCPFHOYA Corporation
$154.17+0.00%
HLNCFHaleon plc
$4.86-2.12%
UCBJYUCB S.A.
$139.01+0.71%
UCBJFUCB S.A.
$290.59+4.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
AALAmerican Airlines Group
$14.48+0.07%

Questions About LZAGF

What is the current price of Lonza Group Ag?

Lonza Group Ag is trading at $675.41 per share.

What is the 52-week range for Lonza Group Ag?

Over the past 52 weeks, Lonza Group Ag has traded between $565.14 and $755.96.

How much debt does Lonza Group Ag have?

As of the most recent reporting period, Lonza Group Ag reported total debt of CHF 5.73B.

How much cash does Lonza Group Ag have on hand?

Lonza Group Ag reported CHF 907.54M in cash and cash equivalents in its most recent financial results.

What is Lonza Group Ag’s dividend yield?

Lonza Group Ag currently has a dividend yield of 0.47%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services